{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:56:36Z","timestamp":1790650596456,"version":"4.1.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Gastroenterol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the perspectives and clinical practice patterns of inflammatory bowel disease (IBD) physicians regarding the use of 5-aminosalicylic acid (5-ASA) in Crohn\u2019s disease (CD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A 21-item questionnaire was distributed to IBD physicians across various regions in mainland China via WeChat. The survey evaluated prescription frequencies, indications, dosages, and physician rationales. The questionnaire was pilot-tested among 30 clinicians of varying seniority levels to ensure clarity and content validity. Responses were anonymized, and duplicate submissions were prevented through WeChat account verification. Statistical analysis employed the chi-square test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 615 respondents, 90.4% reported prescribing 5-ASA for CD patients. It was primarily used for mild disease (91.7%), colonic involvement (77.9%), and non-stricturing, non-penetrating phenotypes (91.4%). For induction therapy, 58.1% of physicians utilized 5-ASA, with 89.2% employing it in combination regimens (predominantly with corticosteroids, 90.3%). Furthermore, 83.1% prescribed 5-ASA for maintenance therapy. The primary rationales cited were its favorable safety profile (75.5%) and perceived efficacy in mild cases (68.2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite unequivocal evidence and international guidelines recommending against the routine use of 5-ASA in CD, it remains pervasively prescribed by Chinese clinicians. This highlights a profound discrepancy between evidence-based guidance and real-world practice. Such therapeutic inertia risks delaying the initiation of highly effective therapies, underscoring an urgent need for targeted continuing medical education to optimize CD management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fgstr.2026.1783772","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:27:29Z","timestamp":1777264049000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Current status of 5-aminosalicylic acid in Crohn\u2019s disease treatment: a nationwide survey and analysis of perspectives and practice patterns among inflammatory bowel disease physicians"],"prefix":"10.3389","volume":"5","author":[{"given":"Yuanli","family":"Li","sequence":"first","affiliation":[{"name":"Department of Gastroenterology Endoscopy Center, Quanzhou First Hospital","place":["Quanzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changxin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Endoscopy Center, Quanzhou First Hospital","place":["Quanzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengdang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Fujian Medical University","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2023-0493","article-title":"Crohn\u2019s disease: an update","volume":"23","author":"Cockburn","year":"2023","journal-title":"Clin Med (Lond)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003463","article-title":"ACG Clinical Guideline Update: Ulcerative colitis in adults","volume":"120","author":"Rubin","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.13105\/wjma.v13.i4.108681","article-title":"Reevaluating aminosalicylates role in maintaining remission in ulcerative colitis: Systematic review and meta-analysis in the era of biologics","volume":"13","author":"Mudege","year":"2025","journal-title":"World J Meta-Anal"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221078456","article-title":"A review of the therapeutic management of Crohn\u2019s disease","volume":"15","author":"Kumar","year":"2022","journal-title":"Ther Adv Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"CD008870","DOI":"10.4324\/9781003271284-16","article-title":"Aminosalicylates for induction of remission or response in Crohn\u2019s disease","volume":"7","author":"Lim","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/mib.0000000000001023","article-title":"Comparative effectiveness of mesalamine, sulfasalazine, corticosteroids, and budesonide for the induction of remission in Crohn\u2019s disease: A Bayesian network meta-analysis","volume":"23","author":"Coward","year":"2017","journal-title":"Inflammation Bowel Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"CD008414","DOI":"10.1002\/14651858.cd008414.pub3","article-title":"Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn\u2019s disease","volume":"6","author":"Gjuladin-Hellon","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"CD003715","DOI":"10.1002\/14651858.cd003715.pub2","article-title":"Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn\u2019s disease","volume":"9","author":"Akobeng","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: Medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2018.27","article-title":"ACG Clinical Guideline: Management of Crohn\u2019s disease in adults","volume":"120","author":"Lichtenstein","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1136\/gutjnl-2024-334395","article-title":"British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025","volume":"74","author":"Moran","year":"2025","journal-title":"Gut"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3760\/cma.j.cn101480-20240108-00006","article-title":"Chinese clinical practice guideline on the management of Crohn\u2032s disease(2023, Guangzhou)","volume":"8","year":"2024","journal-title":"Chin J Inflammation Bowel Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-5181-6","article-title":"Physicians\u2019 perspectives on cost, safety, and perceived efficacy determine aminosalicylate use in Crohn\u2019s disease","volume":"63","author":"Ma","year":"2018","journal-title":"Dig Dis Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/mcg.0000000000000864","article-title":"The use of 5-aminosalicylic acid in children and adolescents with inflammatory bowel disease","volume":"52","author":"Sokollik","year":"2018","journal-title":"J Clin Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2020.0521","article-title":"The use of 5-aminosalicylates in Crohn\u2019s disease: a retrospective study using the UK Clinical Practice Research Datalink","volume":"33","author":"Hart","year":"2020","journal-title":"Ann Gastroenterol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1702020","article-title":"Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective","volume":"20","author":"Allen","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf021","article-title":"Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review","volume":"19","author":"Gisbert","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v12.i24.5468","article-title":"Navigating treatment resistance: Janus kinase inhibitors for ulcerative colitis","volume":"12","author":"Soldera","year":"2024","journal-title":"World J Clin cases"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4240\/wjgs.v15.i11.2579","article-title":"Risk and management of post-operative infectious complications in inflammatory bowel disease: A systematic review","volume":"15","author":"Mowlah","year":"2023","journal-title":"World J Gastrointest Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.07.032","article-title":"Early initiation of tumor necrosis factor antagonist-based therapy for patients with Crohn\u2019s disease reduces costs compared with late initiation","volume":"17","author":"Beilman","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad149","article-title":"Early biologic treatment decreases risk of surgery in Crohn\u2019s disease but not in ulcerative colitis: Systematic review and meta-analysis","volume":"30","author":"Law","year":"2024","journal-title":"Inflammation Bowel Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otab064","article-title":"The effect of early vs delayed initiation of adalimumab on remission rates in patients with Crohn\u2019s disease with poor prognostic factors: The MODIFY study","volume":"3","author":"Mantzaris","year":"2021","journal-title":"Crohns Colitis 360"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2020.001","article-title":"Impact of early anti-TNF use on clinical outcomes in Crohn\u2019s disease: a nationwide population-based study","volume":"35","author":"Jung","year":"2020","journal-title":"Korean J Intern Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.31662\/jmaj.2025-0438","article-title":"Long-term outcomes and therapeutic strategies for newly diagnosed Crohn\u2019s disease in the biologic era: a nationwide claims-based study from Japan","volume":"9","author":"Moroi","year":"2026","journal-title":"JMA J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National Cooperative Crohn\u2019s Disease Study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European Cooperative Crohn\u2019s Disease Study (ECCDS): results of drug treatment","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90337-c","article-title":"Mesalamine capsules for the treatment of active Crohn\u2019s disease: results of a 16-week trial. Pentasa Crohn\u2019s Disease Study Group","volume":"104","author":"Singleton","year":"1993","journal-title":"Gastroenterology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15411","article-title":"Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S-methyltransferase inhibition","volume":"36","author":"Morikubo","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/meg.0b013e3282f16d50","article-title":"Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome","volume":"20","author":"Shah","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200802001-00072","article-title":"Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis","volume":"19","author":"Loftus","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv117","article-title":"Health care cost analysis in a population-based inception cohort of inflammatory bowel disease patients in the first year of diagnosis","volume":"9","author":"Niewiadomski","year":"2015","journal-title":"J Crohns Colitis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1666101","article-title":"Modern use of 5-aminosalicylic acid compounds for ulcerative colitis","volume":"20","author":"Le Berre","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.4234","article-title":"Prevalence, predictors, and clinical consequences of medical adherence in IBD: how to improve it","volume":"15","author":"Lakatos","year":"2009","journal-title":"World J Gastroenterol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/s0002-9343(02)01383-9","article-title":"Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis","volume":"114","author":"Kane","year":"2003","journal-title":"Am J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02809.x","article-title":"Systematic review: adherence issues in the treatment of ulcerative colitis","volume":"23","author":"Kane","year":"2006","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Frontiers in Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2026.1783772\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:27:31Z","timestamp":1777264051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2026.1783772\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":36,"alternative-id":["10.3389\/fgstr.2026.1783772"],"URL":"https:\/\/doi.org\/10.3389\/fgstr.2026.1783772","relation":{},"ISSN":["2813-1169"],"issn-type":[{"value":"2813-1169","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"article-number":"1783772"}}